Q-omics provides the consensus-scored C4orf47 profile across patient tissues and cancer cell-line models. C4orf47 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, C4orf47 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, C4orf47 RNA expression shows 17,943 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KIRC, and UVM as cancer lineages where C4orf47 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C4orf47 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C4orf47 survival associations across molecular data types. C4orf47 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C4orf47 RNA expression–survival associations across cancer types. High C4orf47 expression shows unfavorable associations in LIHC, KICH, LGG and UVM, but favorable associations in UCEC and DLBC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for C4orf47 RNA expression.
This table summarizes C4orf47 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C4orf47. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C4orf47 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, HNSC, COAD and LIHC. The KIRC box plot shows higher C4orf47 RNA expression in tumor versus normal tissue (log2 FC = +1.792, t-test p < 0.001).
This table shows molecular features associated with C4orf47 in patient tissues and cancer cell lines. In patient samples, C4orf47 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C4orf47 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
